Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 11 - 20 of about 75   

Articles published

ARNA 4.16 -0.11 (-2.58%)
price chart
Rebounding Stocks: Arena Pharmaceuticals, Inc.(NASDAQ:ARNA), KiOr Inc ...
Arena Pharmaceuticals, Inc.(NASDAQ:ARNA) traded for as little as $3.82 today, a new 52 week low for the company. However, the company's closing price reflected an eight cent boost from the figure recorded on Sept.
Orexigen Therapeutics Stumbles Off the Edge of a Cliff (ARNA, VVUS, OREX)
On the off chance you need a reminder, Orexigen Therapeutics, Inc. was greatly ballyhooed heading into last week's decision day from the Food and Drug Administration.
Orexigen Therapeutics Wins Contrave Approval But Investors Should Stay Away  Seeking Alpha (registration)
Orexigen Therapeutics, Inc. (NASDAQ:OREX) Obesity Pill Approval Fails to ...  BasicsMedia
Related articles »  
Don't Miss : Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Caterpillar Inc ...
Contrave is a combination of two Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Vivus Inc. drugs that were approved by the FDA in 2012, ABC News reports, after having spent 13 years without approving any weight-loss medication.
Belviq Advertising Sees Major Shift
The anti-obesity drug Belviq from Arena Pharmaceuticals (NASDAQ:ARNA) is finally seeing the type of action in the advertising space that investors can quantify as a compelling shift.
Related articles »  
Top News : GT Advanced Technologies (NASDAQ:GTAT), Arena ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) currently has a Zacks Rank #3 (Hold). Return on Investment for Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is -13.90% and on Friday its shares closed at $4.16. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) ...
Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax ...
Arena Pharmaceuticals Inc.'s stock advanced 1.76%, to close Thursday's session at $4.05, after oscillating between $3.93 and $4.07.
Related articles »  
Hot Watch List: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Galena ...
On 4 September Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) said that stock analysts at Credit Suisse assumed coverage on shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) in a report issued on Thursday. The firm set an �underperform� rating on ...
Related articles »  
Stock Runners: Arena Pharmaceuticals (NASDAQ:ARNA), AT&T, Inc. (NYSE:T ...
On 1 AUG Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) issued its quarterly earnings data on Friday. The company reported $0.03 earnings per share for the quarter, beating the analysts' consensus estimate of ($0.11) by $0.14.
Arena Pharmaceuticals Short Interest Down 5.7% in August (ARNA)
Arena Pharmaceuticals (NASDAQ:ARNA) last posted its quarterly earnings results on Friday, August 1st. The company reported $0.03 earnings per share for the quarter, beating the analysts' consensus estimate of ($0.11) by $0.14. The company had revenue ...
Related articles »  
On The Watch-List: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Miller Energy ...
Dallas, Texas 09/11/2014 (ustradevoice) - Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Eisai will discuss the data from BELVIQ's Phase 3 clinical trial at an event in Austin, Texas.
Worth Watching Stocks �Arena Pharmaceuticals, Inc. (NASDAQ:ARNA ...  Techsonian (press release)
Related articles »